Prevalence and risk factors of hepatitis B and C viruses among haemodialysis patients: a multicentric study

Ali, Niyaz; Hussain, Wajid; Hayat, Azam; Shah, Tariq; Wen, Ronghui; Zeb, Ifra; Malik, Attiya Abdul; Ramzan, Rahdia; REHMAN, MU; Khan, Ibrar

doi:10.1097/meg.0000000000001220

Cited by 16 publications

(21 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, it has been noted that the risk of HBV infection correlates with the sex for example grater were recorded in male with 8.6% in male and 5% in female. In the current study, the frequency of HBV in HD patients from Peshawar is similar to the study reported by [15] with 7.5% from ve HD centers in the Hazara division of Pakistan. Thus, the HD does not increase but signi cantly increase hepatitis C infection rates only [25].…”

Section: Discussionsupporting

confidence: 90%

“…[21] While the study from India conducted by [22] from 1992 to 2000 reported the frequency of HCV in HD was 30% thus HCV among dialysis patients varies markedly from country to country and among dialysis centers within a single country [23]. However, the ratio of HCV is higher in either sex, male or female is not yet clearly understood but we recorded 21% in male and only 20% in female and a similar trend had recorded by [15] with 20.57% in male and 18.18% only in female from Hazara division, Pakistan. While this show contrast with [24] recorded which indicated the ratio of HCV in HD was higher in female as compared to male with 62.50% and 40.13% respectively.…”

Section: Discussionsupporting

confidence: 76%

“…The present study was designed to evaluate the ratio of HBV and HCV in hemodialysis patients. As false positivity is a common problem associated with ICT devices [18] [19] so in order to re ne the screening procedure, we analyzed all the ICT HCV positive samples by RT-PCR which indicated that 22% of the HD had antibodies against HCV which show signi cant decline because PCR is more sensitive to the viral genome [15]. These results reveal that screening of blood and blood products by ICT devices may not predict the true picture of anti-HCV prevalence in HD Patients.…”

Section: Discussionmentioning

confidence: 99%

“…No documented data have been reported on the prevalence of hepatitis viruses among the HD patients in Peshawar, Pakistan, and to the best of our knowledge, this report is the rst to address both HCV and HBV issues. Therefore, the speci c objectives of this study were to investigate the frequency of HBV and HCV among the HD patients of Peshawar, Pakistan, and to assess the major risk factors for transmission of these viruses among HD populations [15].…”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Investigation of Hepatitis B and Hepatitis C in the blood of hemodialysis patients from Peshawar, Pakistan.

Ali

Khan

Salman

et al. 2020

Preprint

View full text Add to dashboard Cite

Abstract Aim: High prevalence of Hepatitis C virus (HCV) and Hepatitis B (HBV) has reported among dialysis patients throughout the world. The aim of this study was to find out the frequency of HCV and HBV both in Hemodialysis (HD) at District Peshawar, the capital of Khyber Pakhtunkhwa Province of Pakistan.Methods: A cross-sectional study was conducted from July 2018 to March 2019. The infections were investigated through serological and molecular techniques. The polymerase chain reaction was performed for only HCV RNA detection in HD patients. The data obtained were compared with available past studies from Pakistan.Results: To evaluate the frequency of HCV, HBV, and co-infection in HD patients. 200 blood samples were collected from dialysis patients who visited Lady Reading Hospital Peshawar. Among 200, HCV infected were diagnosed in 22%, HBV in 8%. The percentages of male to female diagnosed patients with HCV were 21% and 20% respectively. Moreover, the chi-square test of association among variables based on our empirical findings, it is clear that odds of HCV positive among males is 3.467 times greater than female, with statistically significance (P= 0.012*) against 50 and above age group.. Conclusion: The percentage of HCV positive was found higher in the overall HD patient population. Only 7.5% of patients were found Negative of HBV and HCV in both males and females visited hospitals for dialysis. The high prevalence of hepatitis viruses among HD patients indicates a close relation between HD centers and hepatitis virus transmission. Therefore, preventive control measures are essential to reduce hepatitis transmission in HD centers

show abstract

Section: Discussionsupporting

confidence: 90%

Section: Discussionsupporting

confidence: 76%

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Investigation of Hepatitis B and Hepatitis C in the blood of hemodialysis patients from Peshawar, Pakistan.

Ali

Khan

Salman

et al. 2020

Preprint

View full text Add to dashboard Cite

show abstract

“…For example, a prospective, observational study of adult haemodialysis patients randomly selected from 308 dialysis facilities in Europe and the United States during 1988‐2001 demonstrated that the mean HCV prevalence rate was 13.5% and varied from 2.6% to 22.9% between countries . Multiple other studies from various parts of the world reported HCV prevalence between 4% and 40% among patients receiving HD . Given that, even though the prevalence of HCV on HD among Medicare population was substantially higher than in no HD, we believe that our estimate of 4.2% is lower than the true disease burden.…”

Section: Discussionmentioning

confidence: 62%

Prevalence, mortality and healthcare utilization among Medicare beneficiaries with Hepatitis C in Haemodialysis units

Deshpande

Stepanova

Golabi

et al. 2019

Journal of Viral Hepatitis

View full text Add to dashboard Cite

Hepatitis C (HCV) is more common among patients with end-stage renal disease requiring haemodialysis compared to the general population. Thus, we aimed to assess trends in prevalence, health resource utilization and mortality among Medicare beneficiaries with HCV on haemodialysis. This is a retrospective study of outpatient and inpatient claims for Medicare beneficiaries receiving haemodialysis (2005)(2006)(2007)(2008)(2009)(2010)(2011)(2012)(2013)(2014)(2015)(2016).A total of 291 663 subjects on haemodialysis were included (67.3 ± 15.2 years, 55% male, 55% white, 49% age-based eligibility). The prevalence of HCV in subjects on haemodialysis was stable and was significantly higher (mean 4.2% in 2005-2016, P = 0.50 for the trend) than in subjects not on haemodialysis (<1%). In multivariate analysis, liver cirrhosis (odds ratio = 3.4 (95% CI = 3.3-3.6)) was an independent predictor of 1-year mortality among haemodialysis patients. Mean total inpatient payments in dialysis patients with HCV remained stable during 2005 ($73 803) through 2016 ($72 133) (trend P = 0.54) while mean total outpatient payment decreased from 2005 ($53 497) to 2016 ($35 439; trend P = 0.0013). In multivariate analysis, after adjustment for age, gender, race and location, both HCV and cirrhosis remained significant contributors to greater spending [HCV: inpatient

show abstract

HBV vaccination with Fendrix is effective and safe in pre-dialysis CKD population

Fabrizi¹,

Cerutti²,

Nardelli³

et al. 2020

Clinics and Research in Hepatology and Gastroenterology

View full text Add to dashboard Cite

Background: Patients with chronic kidney disease have a poor response to hepatitis B vaccine due to the immunodeficiency conferred from chronic uremia. A recombinant HB vaccine containing an improved adjuvant system AS04 (HBV-AS04) has been manufactured but scarce evidence exists on HBV-AS04 use among patients with CKD. Aim: To assess efficacy and safety of an adjuvanted recombinant vaccine (HBV-AS04) in a large cohort of CKD patients at pre-dialysis stage (with susceptibility to HBV infection). Methods: Patients were prospectively enrolled to receive four 20-mcg doses of HBV-AS04 by intramuscular route (deltoid muscle) at months 1, 2, 3, and 4. Anti-HBs surface antibody concentrations were tested at intervals of 1, 2, 3, 4, and 12 months. Multivariate analyses were performed to assess the parameters, which predicted immunologic response to HBV-AS04 vaccine. Results: One hundred and seven patients were included and 102 completed the study. At completion of vaccine schedule, the frequency of responders (anti-HBs titers ≥ 10 mIU/mL) was 95% (97/102) (mean anti-HBs antibody titers, 688.9 ± 385 mIU/mL), according to per-protocol analysis. Serum haemoglobin levels were greater in responder than non-or low-responder patients to HBV-AS04 (P = 0.04) and this was confirmed by multivariate analysis. The seroprotection rate at month 50 was 88% (30/34) with lower anti-HBs antibody titers (218.5 ± 269.6 mIU/mL, P = 0.001). No major side effects were observed. Conclusions: Our prospective study performed in a real-world setting showed a high immunogenicity and safety of HBV-AS04 vaccine in patients with CKD not yet on maintenance dialysis. Studies provided with longer follow-ups are under way to assess the durability of seroprotection in responders.

show abstract

Prevalence and risk factors of hepatitis B and C viruses among haemodialysis patients: a multicentric study

Abstract: The high prevalence of hepatitis viruses among HD patients of northern Pakistan indicates a close relation between HD centres and hepatitis virus transmission. Therefore, preventive control measures are essential to reduce hepatitis transmission in HD centres.

Cited by 16 publications

References 16 publications

Investigation of Hepatitis B and Hepatitis C in the blood of hemodialysis patients from Peshawar, Pakistan.

Investigation of Hepatitis B and Hepatitis C in the blood of hemodialysis patients from Peshawar, Pakistan.

Prevalence, mortality and healthcare utilization among Medicare beneficiaries with Hepatitis C in Haemodialysis units

HBV vaccination with Fendrix is effective and safe in pre-dialysis CKD population

Contact Info

Product

Resources

About